Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-10
DOI
10.1038/s41467-021-22874-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
- (2020) Sung Choe et al. Blood Advances
- Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
- (2020) Kiyomi Morita et al. Nature Communications
- The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells
- (2019) Biniam Adane et al. Cell Reports
- Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
- (2018) Lynn Quek et al. NATURE MEDICINE
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes
- (2018) Koichi Takahashi et al. Nature Communications
- High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics
- (2018) Maurizio Pellegrino et al. GENOME RESEARCH
- Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells
- (2018) Xingrong Du et al. NATURE
- Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
- (2018) Andrew M. Intlekofer et al. NATURE
- SJARACNe: a scalable software tool for gene network reverse engineering from big data
- (2018) Alireza Khatamian et al. BIOINFORMATICS
- Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
- (2018) James J. Harding et al. Cancer Discovery
- Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
- (2017) Koichi Takahashi et al. LANCET ONCOLOGY
- CD99 is a therapeutic target on disease stem cells in myeloid malignancies
- (2017) Stephen S. Chung et al. Science Translational Medicine
- Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2 - and TET2 -Mutant Acute Myeloid Leukemia
- (2017) Alan H. Shih et al. Cancer Discovery
- Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers
- (2017) Jacob L. Glass et al. Cancer Discovery
- AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
- (2017) Katharine Yen et al. Cancer Discovery
- A 17-gene stemness score for rapid determination of risk in acute leukaemia
- (2016) Stanley W. K. Ng et al. NATURE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- HTSeq--a Python framework to work with high-throughput sequencing data
- (2014) S. Anders et al. BIOINFORMATICS
- IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
- (2014) A. Kernytsky et al. BLOOD
- ChAMP: 450k Chip Analysis Methylation Pipeline
- (2013) Tiffany J. Morris et al. BIOINFORMATICS
- (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
- (2013) J.-A. Losman et al. SCIENCE
- Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
- (2013) F. Wang et al. SCIENCE
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data
- (2012) Andrew E. Teschendorff et al. BIOINFORMATICS
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype
- (2011) V. Grossmann et al. BLOOD
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1
- (2009) S. Zhao et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now